Share on LinkedInShare on LinkedIn

ARTICLE · 13 FEBRUARY 2025

UPC: The Advent Of File Wrapper Estoppel?

Marks & Clerk
Marks & Clerk
Contributor
Marks & Clerk

Marks & Clerk

Marks & Clerk LLP was founded in 1887 by George Croydon Marks, who was joined in partnership by...

View firm profile
Explore more from Marks & Clerk

In two recent decisions before the UPC (UPC_CoA_402/2024, UPC_CoA_405/2024), the Court of Appeal rejected an appeal by Alexion Pharmaceuticals requesting grant of an application...

United KingdomIntellectual Property

In two recent decisions before the UPC (UPC_CoA_402/2024, UPC_CoA_405/2024), the Court of Appeal rejected an appeal by Alexion Pharmaceuticals requesting grant of an application for provisional measures against Amgen and Samsung Bioepis in view of suspected infringement of their European patent. The patent in suit claims an antibody and pharmaceutical composition thereof suitable for use in the treatment of paroxysmal nocturnal hemoglobinuria. In particular, Claim 1 of the patent reads: "An antibody that binds C5 comprising a heavy chain consisting of SEQ ID NO: 2 and a light chain consisting of SEQ ID NO: 4".

The central point of contention in proceedings before the EPO and UPC relates to the interpretation of the sequence of amino acids disclosed as SEQ ID NO: 4. Although the patent discloses SEQ ID NO: 4 under the heading of "Eculizumab Light Chain", the sequence reproduced in the description in fact contains an extra 22 amino acids at the beginning of its

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from